

Karen Leroy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4492272/publications.pdf>

Version: 2024-02-01

114
papers

7,605
citations

53794

45
h-index

53230

85
g-index

118
all docs

118
docs citations

118
times ranked

10137
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862. | 8.5 | 1,002 |
| 2 | Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. <i>Gastroenterology</i> , 2002, 123, 1804-1811. | 1.3 | 535 |
| 3 | The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. <i>Blood</i> , 2007, 109, 4952-4963. | 1.4 | 533 |
| 4 | MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. <i>Blood</i> , 2015, 126, 2466-2474. | 1.4 | 212 |
| 5 | Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019. | 1.4 | 197 |
| 6 | High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. <i>Gut</i> , 2008, 57, 772-779. | 12.1 | 190 |
| 7 | Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2004, 104, 543-549. | 1.4 | 183 |
| 8 | Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. <i>Clinical Cancer Research</i> , 2016, 22, 2919-2928. | 7.0 | 181 |
| 9 | Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nature Genetics</i> , 2014, 46, 329-335. | 21.4 | 180 |
| 10 | Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098. | 1.4 | 173 |
| 11 | Human IL4I1 is a secreted l-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. <i>Blood</i> , 2007, 110, 220-227. | 1.4 | 140 |
| 12 | MAL Expression in Lymphoid Cells: Further Evidence for MAL as a Distinct Molecular Marker of Primary Mediastinal Large B-Cell Lymphomas. <i>Modern Pathology</i> , 2002, 15, 1172-1180. | 5.5 | 138 |
| 13 | Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. <i>Blood</i> , 2004, 103, 2727-2737. | 1.4 | 127 |
| 14 | Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010, 116, 1092-1104. | 1.4 | 122 |
| 15 | The MAL Gene Is Expressed in Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 1999, 94, 3567-3575. | 1.4 | 119 |
| 16 | Erythropoietic protoporphyria in the house mouse. A recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease.. <i>Journal of Clinical Investigation</i> , 1991, 88, 1730-1736. | 8.2 | 116 |
| 17 | Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579. | 1.6 | 113 |
| 18 | Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2009, 114, 1236-1242. | 1.4 | 111 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Prognostic Value of Translocation t(11;18) in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 5061-5066. | 1.6 | 110 |
| 20 | Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1713-1722. | 6.3 | 106 |
| 21 | Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3338-3347. | 7.0 | 98 |
| 22 | Dimethyl fumarate, a two-edged drug: Current status and future directions. <i>Medicinal Research Reviews</i> , 2019, 39, 1923-1952. | 10.5 | 98 |
| 23 | The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. <i>Leukemia</i> , 2008, 22, 1917-1924. | 7.2 | 95 |
| 24 | <i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> -mutated urothelial bladder carcinoma. <i>Journal of Pathology</i> , 2012, 227, 315-324. | 4.5 | 90 |
| 25 | The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , 2019, 17, 357. | 4.4 | 88 |
| 26 | Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. <i>Molecular Cancer</i> , 2004, 3, 20. | 19.2 | 85 |
| 27 | p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , 2002, 13, 1108-1115. | 1.2 | 84 |
| 28 | Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 860-866. | 1.1 | 84 |
| 29 | Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2232-2244. | 7.0 | 82 |
| 30 | DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 491-500. | 2.8 | 80 |
| 31 | Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003. | 1.6 | 79 |
| 32 | Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930. | 4.1 | 79 |
| 33 | Human Interleukin-10 Expression in T/Natural Killer-Cell Lymphomas. <i>American Journal of Pathology</i> , 1998, 153, 1229-1237. | 3.8 | 75 |
| 34 | Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 251-267. | 2.8 | 75 |
| 35 | Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 436-441. | 2.6 | 73 |
| 36 | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473. | 3.7 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. <i>Haematologica</i> , 2015, 100, e280-e284. | 3.5 | 69 |
| 38 | Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2003, 101, 2756-2761. | 1.4 | 61 |
| 39 | Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?. <i>Annals of Oncology</i> , 2005, 16, 1232-1236. | 1.2 | 57 |
| 40 | Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 529-539. | 4.1 | 54 |
| 41 | CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of SÅ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2008, 128, 465-472. | 0.7 | 51 |
| 42 | Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 273-283. | 2.8 | 50 |
| 43 | Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. <i>Annals of Oncology</i> , 2016, 27, 1311-1316. | 1.2 | 49 |
| 44 | Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1. <i>Clinical Cancer Research</i> , 2007, 13, 398-407. | 7.0 | 48 |
| 45 | A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer. <i>PLoS ONE</i> , 2012, 7, e48993. | 2.5 | 47 |
| 46 | Identification of Genes Potentially Involved in the Increased Risk of Malignancy in NF1-Microdeleted Patients. <i>Molecular Medicine</i> , 2011, 17, 79-87. | 4.4 | 46 |
| 47 | MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. <i>BMC Genomics</i> , 2013, 14, 473. | 2.8 | 46 |
| 48 | Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. <i>Leukemia and Lymphoma</i> , 2010, 51, 284-290. | 1.3 | 45 |
| 49 | The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis. <i>Clinical Cancer Research</i> , 2014, 20, 358-371. | 7.0 | 44 |
| 50 | STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-Cell lymphoma. <i>Leukemia</i> , 2008, 22, 2106-2110. | 7.2 | 43 |
| 51 | Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial - the PRODIGE 22 - ECKINOXE trial. <i>BMC Cancer</i> , 2015, 15, 511. | 2.6 | 43 |
| 52 | Involvement of the Leptin Receptor in the Immune Response in Intestinal Cancer. <i>Cancer Research</i> , 2008, 68, 9413-9422. | 0.9 | 40 |
| 53 | Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 892-904. | 2.8 | 39 |
| 54 | Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. <i>Blood</i> , 2018, 131, 2036-2046. | 1.4 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas. <i>Oncogene</i> , 1998, 17, 1245-1251. | 5.9 | 38 |
| 56 | Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1898-1907. | 1.3 | 36 |
| 57 | Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. <i>Human Pathology</i> , 2001, 32, 196-204. | 2.0 | 34 |
| 58 | Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , 2004, 10, 3763-3771. | 7.0 | 34 |
| 59 | Fate of β -Hemoglobin Chains and Erythrocyte Defects in β -Thalassemia. <i>Annals of the New York Academy of Sciences</i> , 1990, 612, 106-117. | 3.8 | 32 |
| 60 | STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). <i>Oncotarget</i> , 2013, 4, 1093-1102. | 1.8 | 32 |
| 61 | Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. <i>Leukemia and Lymphoma</i> , 2013, 54, 940-944. | 1.3 | 29 |
| 62 | Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. <i>Oncotarget</i> , 2018, 9, 9088-9099. | 1.8 | 29 |
| 63 | Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles. <i>EBioMedicine</i> , 2019, 48, 58-69. | 6.1 | 29 |
| 64 | The alternative RelB NF- κ B subunit is a novel critical player in diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 384-398. | 1.4 | 29 |
| 65 | Mucosa-associated lymphoid tissue lymphoma of the thymus: a case report with no evidence of MALT1 rearrangement. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 189-193. | 2.8 | 28 |
| 66 | Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human. <i>Molecular Brain Research</i> , 2003, 114, 55-64. | 2.3 | 24 |
| 67 | Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas. <i>Oncogene</i> , 2006, 25, 2807-2811. | 5.9 | 23 |
| 68 | Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience. <i>PLoS ONE</i> , 2013, 8, e68945. | 2.5 | 23 |
| 69 | Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 205-214. | 2.8 | 23 |
| 70 | BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049. | 1.2 | 21 |
| 71 | Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. <i>European Journal of Cancer</i> , 2022, 166, 87-99. | 2.8 | 21 |
| 72 | Antiproliferative Effect of Semaphorin 3F on Human Melanoma Cell Lines. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2343-2345. | 0.7 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 619-628. | 3.7 | 19 |
| 74 | BRAF V600E mutations in bile duct adenomas. <i>Hepatology</i> , 2015, 61, 403-405. | 7.3 | 19 |
| 75 | Redifferentiating Effect of Larotrectinib in <i>NTRK</i> -Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 594-598. | 4.5 | 19 |
| 76 | Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation. <i>British Journal of Cancer</i> , 2003, 88, 388-395. | 6.4 | 18 |
| 77 | Mucosa-associated lymphoid tissue lymphoma in patients with human immunodeficiency virus infection. <i>British Journal of Haematology</i> , 2008, 140, 470-474. | 2.5 | 18 |
| 78 | Differential Expression of <i>CCN1</i> , <i>CYR61</i> , <i>CCN3/NOV</i> , <i>CCN4/WISP1</i> , and <i>CCN5/WISP2</i> in Neurofibromatosis Type 1 Tumorigenesis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 60-69. | 1.7 | 16 |
| 79 | Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. <i>Haematologica</i> , 2017, 102, e404-e406. | 3.5 | 16 |
| 80 | STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma. <i>Cellular Signalling</i> , 2018, 46, 76-82. | 3.6 | 15 |
| 81 | Primary Hepatic Lymphoma of Mucosa-Associated Lymphoid Tissue Type: A Case Report With Cytogenetic Study. <i>International Journal of Surgical Pathology</i> , 2008, 16, 301-307. | 0.8 | 14 |
| 82 | Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. <i>BMC Cancer</i> , 2013, 13, 472. | 2.6 | 11 |
| 83 | Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis. <i>Journal of Hepatology</i> , 2003, 38, 866-869. | 3.7 | 10 |
| 84 | SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog. <i>Human Pathology</i> , 2011, 42, 434-443. | 2.0 | 10 |
| 85 | The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas. <i>PLoS ONE</i> , 2019, 14, e0214416. | 2.5 | 10 |
| 86 | EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. <i>Cancers</i> , 2021, 13, 5132. | 3.7 | 9 |
| 87 | Is Elevated Gastric Tissue NOX2 Associated with Lymphoma of Mucosa-Associated Lymphoid Tissue?. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 1205-1211. | 5.4 | 7 |
| 88 | c-Rel Is the Pivotal NF- κ B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. <i>Frontiers in Oncology</i> , 2021, 11, 638897. | 2.8 | 7 |
| 89 | Standardisation of pathogenicity classification for somatic alterations in solid tumours and haematologic malignancies. <i>European Journal of Cancer</i> , 2021, 159, 1-15. | 2.8 | 7 |
| 90 | ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type. <i>Leukemia Research</i> , 2013, 37, 3-8. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program. Blood, 2012, 120, 415-415. | 1.4 | 6 |
| 92 | Isolated 5â€² Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature. Translational Oncology, 2019, 12, 784-787. | 3.7 | 5 |
| 93 | R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. Blood, 2011, 118, 2632-2632. | 1.4 | 5 |
| 94 | Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis. Leukemia and Lymphoma, 2009, 50, 410-418. | 1.3 | 4 |
| 95 | Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma. Molecular Carcinogenesis, 2010, 49, 25-31. | 2.7 | 4 |
| 96 | Accurate Classification Of GCB/ABC and MYC/BCL2 Diffuse Large B-Cell Lymphoma With a 14 Genes Expression Signature and a Simple and Robust RT-MLPA Assay. Blood, 2013, 122, 84-84. | 1.4 | 3 |
| 97 | Targeting STAT6 in PMBL. Oncotarget, 2014, 5, 7216-7216. | 1.8 | 3 |
| 98 | Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers. British Journal of Cancer, 2022, 127, 1123-1132. | 6.4 | 3 |
| 99 | DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomy. World Journal of Urology, 2014, 32, 899-904. | 2.2 | 2 |
| 100 | Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study. Blood, 2015, 126, 129-129. | 1.4 | 2 |
| 101 | Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. European Journal of Endocrinology, 2022, 186, 607-617. | 3.7 | 2 |
| 102 | Expression of MYC, IgM, As Well As Non-Germinal Centre B-Cell Like Immunophenotype and Positive Immunofish Index Predict a Worse Progression Free Survival and Overall Survival in a Series of 670 De Novo Diffuse Large B-Cell Lymphomas Included in Clinical Trials: A GELA Study of the 2003 Program. Blood, 2012, 120, 1539-1539. | 1.4 | 1 |
| 103 | Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. Blood, 2013, 122, 242-242. | 1.4 | 1 |
| 104 | Correlations between p53 overexpression, serum antibodies and gene mutation in colorectal cancer. Gastroenterology, 1998, 114, A605. | 1.3 | 0 |
| 105 | Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts). Annals of Oncology, 2016, 27, vi29. | 1.2 | 0 |
| 106 | Identification of patients at risk for severe toxicity under PD1 inhibitors: role of sarcopenic overweight. Annals of Oncology, 2016, 27, vi373. | 1.2 | 0 |
| 107 | Authorsâ€™ Reply. Journal of Molecular Diagnostics, 2018, 20, 266. | 2.8 | 0 |
| 108 | BCL2 Negative Follicular Lymphoma with BCL6 Gene Rearrangement Show Mutations of STAT6 DNA Binding Domain. Blood, 2012, 120, 1559-1559. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing. , 2015, , . | | 0 |
| 110 | Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study. Blood, 2015, 126, 1472-1472. | 1.4 | 0 |
| 111 | Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.. Journal of Clinical Oncology, 2016, 34, 7547-7547. | 1.6 | 0 |
| 112 | A multidisciplinary team dedicated to the management of patients treated with PD1 inhibitors: The Cochin hospital experience.. Journal of Clinical Oncology, 2016, 34, e18208-e18208. | 1.6 | 0 |
| 113 | Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and Non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Blood, 2016, 128, 4097-4097. | 1.4 | 0 |
| 114 | Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 4118-4118. | 1.4 | 0 |